Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX) and HUTCHMED (HCM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bicara Therapeutics Inc. (BCAX – Research Report) and HUTCHMED (HCM – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Bicara Therapeutics Inc. (BCAX)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Bicara Therapeutics Inc. today and set a price target of $40.00. The company’s shares closed last Monday at $18.51.

According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.4% and a 39.6% success rate. Burns covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Black Diamond Therapeutics, and ArriVent BioPharma, Inc. ;'>

Bicara Therapeutics Inc. has an analyst consensus of Strong Buy, with a price target consensus of $31.67, which is a 70.7% upside from current levels. In a report issued on September 29, JonesTrading also maintained a Buy rating on the stock with a $22.00 price target.

See the top stocks recommended by analysts >>

HUTCHMED (HCM)

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on HUTCHMED, with a price target of $25.00. The company’s shares closed last Monday at $15.39.

According to TipRanks.com, Stranahan is a 3-star analyst with an average return of 1.4% and a 54.3% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Recursion Pharmaceuticals, and Perspective Therapeutics. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for HUTCHMED with a $17.92 average price target.

Read More on BCAX:

Disclaimer & DisclosureReport an Issue

• Bicara Therapeutics announces ficerafusp alfa granted BTD by U.S. FDA
• Bicara Therapeutics files $400M mixed securities shelf
• Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating
• Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside
• Bicara Therapeutics initiated with a Buy at JonesResearch